373 related articles for article (PubMed ID: 8595163)
21. Effect of single and multiple administration of an O6-benzylguanine/temozolomide combination: an evaluation in a human melanoma xenograft model.
Wedge SR; Porteous JK; Newlands ES
Cancer Chemother Pharmacol; 1997; 40(3):266-72. PubMed ID: 9219512
[TBL] [Abstract][Full Text] [Related]
22. O6-methylguanine-DNA methyltransferase (MGMT) transfectants of a 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU)-sensitive colon cancer cell line selectively repopulate heterogenous MGMT+/MGMT- xenografts after BCNU and O6-benzylguanine plus BCNU.
Phillips WP; Willson JK; Markowitz SD; Zborowska E; Zaidi NH; Liu L; Gordon NH; Gerson SL
Cancer Res; 1997 Nov; 57(21):4817-23. PubMed ID: 9354444
[TBL] [Abstract][Full Text] [Related]
23. New cytotoxic agents for the treatment of metastatic malignant melanoma: temozolomide and related alkylating agents in combination with guanine analogues to abrogate drug resistance.
Spiro T; Liu L; Gerson S
Forum (Genova); 2000; 10(3):274-85. PubMed ID: 11007934
[TBL] [Abstract][Full Text] [Related]
24. O6-benzylguanine-mediated enhancement of chemotherapy.
Friedman HS; Keir S; Pegg AE; Houghton PJ; Colvin OM; Moschel RC; Bigner DD; Dolan ME
Mol Cancer Ther; 2002 Sep; 1(11):943-8. PubMed ID: 12481416
[TBL] [Abstract][Full Text] [Related]
25. Increased killing of prostate, breast, colon, and lung tumor cells by the combination of inactivators of O6-alkylguanine-DNA alkyltransferase and N,N'-bis(2-chloroethyl)-N-nitrosourea.
Pegg AE; Swenn K; Chae MY; Dolan ME; Moschel RC
Biochem Pharmacol; 1995 Oct; 50(8):1141-8. PubMed ID: 7488227
[TBL] [Abstract][Full Text] [Related]
26. The effects of O6-benzylguanine and hypoxia on the cytotoxicity of 1,3-bis(2-chloroethyl)-1-nitrosourea in nitrosourea-resistant SF-763 cells.
Sarkar A; Dolan ME; Gonzalez GG; Marton LJ; Pegg AE; Deen DF
Cancer Chemother Pharmacol; 1993; 32(6):477-81. PubMed ID: 8258197
[TBL] [Abstract][Full Text] [Related]
27. Effect of temozolomide and dacarbazine on O6-alkylguanine-DNA alkyltransferase activity and sensitivity of human tumor cells and xenografts to 1,3-bis(2-chloroethyl)-1-nitrosourea.
Mitchell RB; Dolan ME
Cancer Chemother Pharmacol; 1993; 32(1):59-63. PubMed ID: 8462125
[TBL] [Abstract][Full Text] [Related]
28. Potentiation of BCNU antitumor efficacy by 9-substituted O6-benzylguanines. Effect of metabolism.
Kokkinakis DM; Moschel RC; Pegg AE; Schold SC
Cancer Chemother Pharmacol; 2000; 45(1):69-77. PubMed ID: 10647505
[TBL] [Abstract][Full Text] [Related]
29. Point mutations in human O6-alkylguanine-DNA alkyltransferase prevent the sensitization by O6-benzylguanine to killing by N,N'-bis (2-chloroethyl)-N-nitrosourea.
Loktionova NA; Pegg AE
Cancer Res; 1996 Apr; 56(7):1578-83. PubMed ID: 8603405
[TBL] [Abstract][Full Text] [Related]
30. Selection for G156A O6-methylguanine DNA methyltransferase gene-transduced hematopoietic progenitors and protection from lethality in mice treated with O6-benzylguanine and 1,3-bis(2-chloroethyl)-1-nitrosourea.
Davis BM; Reese JS; Koç ON; Lee K; Schupp JE; Gerson SL
Cancer Res; 1997 Nov; 57(22):5093-9. PubMed ID: 9371508
[TBL] [Abstract][Full Text] [Related]
31. In vitro evaluation of temozolomide combined with X-irradiation.
Wedge SR; Porteous JK; Glaser MG; Marcus K; Newlands ES
Anticancer Drugs; 1997 Jan; 8(1):92-7. PubMed ID: 9147618
[TBL] [Abstract][Full Text] [Related]
32. O6-alkylguanine DNA-alkyltransferase is not a major determinant of sensitivity to 1,3-bis(2-chloroethyl)-1-nitrosourea in four medulloblastoma cell lines.
Silber JR; Bobola MS; Ewers TG; Muramoto M; Berger MS
Oncol Res; 1992; 4(6):241-8. PubMed ID: 1421617
[TBL] [Abstract][Full Text] [Related]
33. G156A MGMT-transduced human mesenchymal stem cells can be selectively enriched by O6-benzylguanine and BCNU.
Lee K; Gerson SL; Maitra B; Koç ON
J Hematother Stem Cell Res; 2001 Oct; 10(5):691-701. PubMed ID: 11672516
[TBL] [Abstract][Full Text] [Related]
34. Role of codon 160 in the sensitivity of human O6-alkylguanine-DNA alkyltransferase to O6-benzylguanine.
Xu-Welliver M; Leitão J; Kanugula S; Meehan WJ; Pegg AE
Biochem Pharmacol; 1999 Oct; 58(8):1279-85. PubMed ID: 10487529
[TBL] [Abstract][Full Text] [Related]
35. Mechanisms of resistance to 1,3-bis(2-chloroethyl)-1-nitrosourea in human medulloblastoma and rhabdomyosarcoma.
Bacolod MD; Johnson SP; Ali-Osman F; Modrich P; Bullock NS; Colvin OM; Bigner DD; Friedman HS
Mol Cancer Ther; 2002 Jul; 1(9):727-36. PubMed ID: 12479369
[TBL] [Abstract][Full Text] [Related]
36. Depletion of O6-alkylguanine-DNA alkyltransferase correlates with potentiation of temozolomide and CCNU toxicity in human tumour cells.
Baer JC; Freeman AA; Newlands ES; Watson AJ; Rafferty JA; Margison GP
Br J Cancer; 1993 Jun; 67(6):1299-302. PubMed ID: 8512814
[TBL] [Abstract][Full Text] [Related]
37. Quantitative relationship between guanine O(6)-alkyl lesions produced by Onrigin™ and tumor resistance by O(6)-alkylguanine-DNA alkyltransferase.
Ishiguro K; Zhu YL; Shyam K; Penketh PG; Baumann RP; Sartorelli AC
Biochem Pharmacol; 2010 Nov; 80(9):1317-25. PubMed ID: 20654586
[TBL] [Abstract][Full Text] [Related]
38. Hematopoietic expression of O(6)-methylguanine DNA methyltransferase-P140K allows intensive treatment of human glioma xenografts with combination O(6)-benzylguanine and 1,3-bis-(2-chloroethyl)-1-nitrosourea.
Kreklau EL; Pollok KE; Bailey BJ; Liu N; Hartwell JR; Williams DA; Erickson LC
Mol Cancer Ther; 2003 Dec; 2(12):1321-9. PubMed ID: 14707273
[TBL] [Abstract][Full Text] [Related]
39. Differential competitive resistance to methylating versus chloroethylating agents among five O6-alkylguanine DNA alkyltransferases in human hematopoietic cells.
Fontes AM; Davis BM; Encell LP; Lingas K; Covas DT; Zago MA; Loeb LA; Pegg AE; Gerson SL
Mol Cancer Ther; 2006 Jan; 5(1):121-8. PubMed ID: 16432170
[TBL] [Abstract][Full Text] [Related]
40. Cytotoxicity of fluoroethylating agents is potentiated by O6-benzylguanine.
Terashima I; Kohda K
Biol Pharm Bull; 1996 Jul; 19(7):956-61. PubMed ID: 8839969
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
